| Patents for G01N 33 - Investigating or analysing materials by specific methods not covered by groups (393,632) |
|---|
| 02/27/2003 | WO2003015692A2 Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| 02/27/2003 | WO2003015636A1 Body fluid collection and analysis |
| 02/27/2003 | WO2003015631A1 Spectroscopic breath analysis |
| 02/27/2003 | WO2003015627A2 In-situ adapter for an analyte testing device |
| 02/27/2003 | WO2003015617A2 Assay method for alzheimer's disease |
| 02/27/2003 | WO2003015613A2 Molecular characteristics of non-small cell lung cancer |
| 02/27/2003 | WO2003015517A1 Agonists and antagonists of 5h3-like receptors of invertebrate s as pesticides |
| 02/27/2003 | WO2003015507A1 Development of transgenic model for interventions in neurodegenerative diseases |
| 02/27/2003 | WO2003015506A1 Propagation of human hepatoblastoma cell in non-human animals |
| 02/27/2003 | WO2003007711A8 Microstructures for cell proliferation assays and semen analysis |
| 02/27/2003 | WO2003001881A3 Cell-based high-throughput screening methods |
| 02/27/2003 | WO2003001178A3 Configurable dynamic three dimensional array |
| 02/27/2003 | WO2002103000A3 Methods for modulating gap junctions |
| 02/27/2003 | WO2002102988A3 Method for neural stem cell differentiation using 5ht-1a agonists |
| 02/27/2003 | WO2002102977A9 Characterization of a membrane estrogen receptor |
| 02/27/2003 | WO2002101356A3 Organellar proteomics including determination of targets for therapeutic intervention identified in the mitochondrial proteome using mass spectrometry |
| 02/27/2003 | WO2002101355A3 Improved proteomic analysis |
| 02/27/2003 | WO2002099378A3 Methods of identifying anti-cancer agents that are inducers of apoptosis |
| 02/27/2003 | WO2002097046A3 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | WO2002095395A3 Benzophenone-linked crf and crf-like peptides for covalent labeling of corticotropin-releasing factor (crf) binding protein |
| 02/27/2003 | WO2002092763A3 Intron associated with myotonic dystrophy type 2 and methods of use |
| 02/27/2003 | WO2002090994A3 Individualization of therapy with analgesics |
| 02/27/2003 | WO2002090958A3 Sessor and sensing method for detection and process control |
| 02/27/2003 | WO2002090920A3 Method and device for determining a characteristic value that is representative of the condition of a gas |
| 02/27/2003 | WO2002090518A3 Differential regulation of t cell survival and proliferation |
| 02/27/2003 | WO2002089744A3 Combined treatments and methods of treatment of mycoplasma and mycoplasma-like organism infections |
| 02/27/2003 | WO2002089657A3 Diagnostic markers of acute coronary syndromes and methods of use thereof |
| 02/27/2003 | WO2002088714A3 Individualization of therapy with antineoplastic agents |
| 02/27/2003 | WO2002086154A8 Methods for generating libraries of therapeutic bacteriophages having desired safety characteristics and methods for labeling and monitoring bacteriophages |
| 02/27/2003 | WO2002083923A3 Methods for quantification and de novo polypeptide sequencing by mass spectrometry |
| 02/27/2003 | WO2002081638A3 Prostate cancer expression profiles |
| 02/27/2003 | WO2002080845A3 Novel eps8 compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002080844A3 Novel bgp compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002077748A3 Light scatteringdetermination of treatment potencies |
| 02/27/2003 | WO2002077169A3 Methods of detecting dissociated nuclear hormone receptor ligands |
| 02/27/2003 | WO2002077167A3 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof |
| 02/27/2003 | WO2002074927A3 High accuracy protein identification |
| 02/27/2003 | WO2002072752A3 Forms of prostate specific antigens and methods for their detection |
| 02/27/2003 | WO2002071040A3 Use of infrared spectroscopy in genotypic analysis |
| 02/27/2003 | WO2002068453A3 Methods and compositions for the construction and use of fusion libraries using computational protein design methods |
| 02/27/2003 | WO2002066973A3 Method and apparatus for calibration of instruments that monitor the concentration of a sterilant in a system |
| 02/27/2003 | WO2002066656A3 Detection of protein conformation using a split ubiquitin reporter system |
| 02/27/2003 | WO2002066602A3 Detection of allergen-specific ige |
| 02/27/2003 | WO2002065127A3 A system and method for characterizing the permittivity of molecular events |
| 02/27/2003 | WO2002064815A3 33945, a human glycosyltransferase family member and uses therefor |
| 02/27/2003 | WO2002062956A3 Chemomagnetic retrieval of cmv and cmv infected cells |
| 02/27/2003 | WO2002062203A3 Compositions and methods for the therapy and diagnosis of breast cancer |
| 02/27/2003 | WO2002061425A3 Diagnostic method and apparatus for detecting biogenic amines |
| 02/27/2003 | WO2002059561A3 Modular computational models for predicting the pharmaceutical properties of chemical compounds |
| 02/27/2003 | WO2002057764A3 Means for initiating a self-test |
| 02/27/2003 | WO2002057422A3 Ternary biomolecule/polymer/surface-based immobilization systems |
| 02/27/2003 | WO2002056908A3 Artificial antigen-presenting cells |
| 02/27/2003 | WO2002056489A3 Local oscillator leakage control in direct conversion processes |
| 02/27/2003 | WO2002056029A3 Occult blood test enhancer |
| 02/27/2003 | WO2002055555A3 Antigenic ck-18 compounds for therapy and diagnosis and methods for using same |
| 02/27/2003 | WO2002053777A3 Device and method for tracking conditions in an assay |
| 02/27/2003 | WO2002048710A3 Method for determining concentrations of analytes |
| 02/27/2003 | WO2002048393A3 Light-activated in vitro assay process for luciferase bioluminescence |
| 02/27/2003 | WO2002048375A3 Purified active hcv ns2/3 protease |
| 02/27/2003 | WO2002048184A3 Glycoprotein peptide of the human herpesvirus-7 for use in particular in an elisa serologic test |
| 02/27/2003 | WO2002044336A3 Method of making a protein polymer and uses of the polymer |
| 02/27/2003 | WO2002042436A3 Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof |
| 02/27/2003 | WO2002036136A3 Compositions and methods for prolonging survival of chilled platelets |
| 02/27/2003 | WO2002034950A3 Immobilization of biopolymers to aminated substrates by direct adsorption |
| 02/27/2003 | WO2002023200A3 Human breast cancer biomarkers |
| 02/27/2003 | WO2002021133A3 Methods of detecting cancer based on prostasin |
| 02/27/2003 | WO2002017711A3 Therapeutics and diagnostics based on a novel signal transduction system in platelets |
| 02/27/2003 | WO2002016948A3 High throughput method and kit |
| 02/27/2003 | WO2002016548A8 Novel g protein-coupled receptor |
| 02/27/2003 | WO2002014875A3 Method and system for predicting amino acid sequence |
| 02/27/2003 | WO2002014555A3 Single-labeled oligonucleotide probes |
| 02/27/2003 | WO2002012290A8 Sid polypeptides binding to pathogenic strain of the hepatitis c virus |
| 02/27/2003 | WO2002010459A3 Three dimensional structure of paramyxovirus hemagglutinin-neuraminidases and use thereof |
| 02/27/2003 | WO2002008716A3 Method for screening peptides for use in immunotherapy |
| 02/27/2003 | WO2002008407A9 Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring |
| 02/27/2003 | WO2002008267A3 Compounds and methods for treatment and diagnosis of chlamydial infection |
| 02/27/2003 | WO2002003058A3 Device and method for making electrical contact with biological cells suspended in a fluid |
| 02/27/2003 | WO2002002797A3 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme |
| 02/27/2003 | WO2002001950A3 Transgenic mice containing targeted gene disruptions |
| 02/27/2003 | WO2002000691A3 Polynucleotides and polypeptides encoded thereby |
| 02/27/2003 | WO2001098543A3 Method of diagnosing, monitoring, staging, imaging and treating breast cancer |
| 02/27/2003 | WO2001098471A3 Human phosphodiesterases |
| 02/27/2003 | WO2001098457A3 Surface model of a protein |
| 02/27/2003 | WO2001092892A3 Methods to identify compounds that modulate rage |
| 02/27/2003 | WO2001069253A3 3d model of an fc epsilon receptor alpha chain-ige fc region complex |
| 02/27/2003 | WO2001061050A3 Methods and compositions for the identification, assessment, prevention and therapy of human cancers |
| 02/27/2003 | US20030041345 Nucleotide sequences coding enzymatic polypeptide for use in the propagation of plants |
| 02/27/2003 | US20030041344 Receptor kinase, BIN1 |
| 02/27/2003 | US20030041341 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in DNA encoding 4E-BP1 |
| 02/27/2003 | US20030041339 Animal model for use in the treatment of vision defects |
| 02/27/2003 | US20030040892 Method for modeling the transport of ions in hydrated cement systems |
| 02/27/2003 | US20030040665 Systems and methods of pH tissue monitoring |
| 02/27/2003 | US20030040660 Method for diagnosing and distinguishing traumatic brain injury and diagnostic devices for use therein |
| 02/27/2003 | US20030040621 Chromatography material and a method using same |
| 02/27/2003 | US20030040607 Hematopoietic cell E-selection/L-selectin ligand polypeptides and methods of use thereof |
| 02/27/2003 | US20030040602 Biopolymer for use in the accurate diagnosis of heart, stroke and congestive heart failure |
| 02/27/2003 | US20030040509 Methods and compositions for treating diseases associated with excesses in ACE |
| 02/27/2003 | US20030040505 Synthetic phospholipids to ameliorate atherosclerosis and other inflammatory conditions |
| 02/27/2003 | US20030040500 Replication incompetent herpes virus vectors |
| 02/27/2003 | US20030040495 Collecting tissue; determining amount of mitochondrial DNA damage in tissue; comparing the amount of mitochondrial DNA damage in tissue of interest to the amount of mitochondrial DNA damage in tissue of interest from a control |